The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

NCT00401310 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

150

Enrollment

INDUSTRY

Sponsor class

Stopped Termination date was 20-Oct-2008. Subjects were monitored during the post treatment 90 day follow-up period (per protocol) resulting in LPLV 19-Jan-2009.

Conditions

Middle Cerebral Artery Stroke

Interventions

DRUG: Comparator: Placebo
DRUG: Comparator: MK0724

Sponsor

Merck Sharp & Dohme LLC